EGFR and non-small cell lung carcinoma: With the publication of randomized controlled clinical trials, such as ADJUVANT, ADAURA, EVIDENCE, and EVAN, more optimized targeted treatment regimens have been developed for postoperative adjuvant therapy for patients with EGFR-mutated NSCLC [2].